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Conventionally, facultative intracellular pathogen, Mycobacterium tuberculosis, the
tuberculosis (TB) causing bacilli in human is cleared by cell-mediated immunity (CMI)
with CD4+ T cells playing instrumental role in protective immunity, while antibody-
mediated immunity (AMI) is considered non-protective. This longstanding convention
has been challenged with recent evidences of increased susceptibility of hosts with
compromised AMI and monoclonal antibodies conferring passive protection against
TB and other intracellular pathogens. Therefore, novel approaches toward vaccine
development include strategies aiming at induction of humoral response along with
CMI. This necessitates the identification of mycobacterial proteins with properties
of immunomodulation and strong immunogenicity. In this study, we determined the
immunogenic potential of M. tuberculosis Zinc metalloprotease-1 (Zmp1), a secretory
protein essential for intracellular survival and pathogenesis of M. tuberculosis. We
observed that Zmp1 was secreted by in vitro grown M. tuberculosis under granuloma-
like stress conditions (acidic, oxidative, iron deficiency, and nutrient deprivation) and
generated Th2 cytokine microenvironment upon exogenous treatment of peripheral
blood mononulear cells PBMCs with recombinant Zmp1 (rZmp1). This was supported
by recording specific and robust humoral response in TB patients in a cohort of 295.
The anti-Zmp1 titers were significantly higher in TB patients (n = 121) as against healthy
control (n = 62), household contacts (n = 89) and non-specific infection controls
(n = 23). A significant observation of the study is the presence of equally high titers
of anti-Zmp1 antibodies in a range of patients with high bacilli load (sputum bacilli load
of 300+ per mL) to paucibacillary smear-negative pulmonary tuberculosis (PTB) cases.
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This clearly indicated the potential of Zmp1 to evoke an effective humoral response
independent of mycobacterial load. Such mycobacterial proteins can be explored as
antigen candidates for prime-boost vaccination strategies or extrapolated as markers
for disease detection and progression.
Keywords: tuberculosis (TB), extra-pulmonary tuberculosis (EPTB), pulmonary tuberculosis (PTB), Rv0198c,
humoral immunity
INTRODUCTION
Mycobacterium tuberculosis, the tuberculosis (TB) causing
bacilli are facultative intracellular parasite, residing primarily
in phagocytic cells like alveolar macrophages and monocytes,
but may also colonize other cells, such as alveolar epithelial
cells, bones, meninges, peritoneal linings of the intestines, etc.
(Golden and Vikram, 2005). Traditionally, like all intracellular
pathogens, protective immunity to M. tuberculosis has been
credited to the cell mediated immunity (CMI) with CD4+ T cells
playing a crucial role in granuloma formation while antibody
mediated immunity (AMI) is considered non-protective (van
Crevel et al., 2002). The argument that M. tuberculosis is strictly
intracellular, however, is debatable as M. tuberculosis, during
some point of its infectious cycle, has also been observed in
extracellular spaces (Grosset, 2003), where in principle they can
be vulnerable to antibody action. There are a number of reports
where despite being intracellular pathogen, antibodies have been
shown to modulate the immune response in favor of the host
against pathogens (Casadevall, 2003). Studies with antibodies,
monoclonal or otherwise, have now demonstrated passive
protection for several microbes, such as Candida albicans (Han
and Cutler, 1995), Listeria monocytogenes (Edelson et al., 1999),
Leishmania mexicana (Anderson et al., 1983), M. tuberculosis
(Teitelbaum et al., 1998; Zhao et al., 2011) etc., though
experiments with immune serum have provided inconsistent
results. Similarly, a considerable expanse of data propose that
defense against intracellular and extracellular pathogens are not
stringently restricted to either Th1 (promoting CMI) or Th2
(promoting AMI) responses. Citing a few examples, humoral
immunity have been shown to be protective against intracellular
pathogens like Plasmodium or Mycobacteria, while protective
immunity against extracellular parasitic flatworm Schistosoma
was due to CMI triggered by Th1 response (Abebe and Bjune,
2009; Greenhouse et al., 2011; Wen et al., 2011; Dups et al.,
2014). Recently, Modified Vaccinia Ankara 85A (MVA85A) failed
to clear the phase 2b trial, where M. tuberculosis major secreted
antigen complex 85A (Ag85A) that induces a strong Th1 immune
response in BCG-primed host was used (Tameris et al., 2013).
Therefore, though CMI may remain the mainstream immune
response, the role of AMI in conferring protection against
intracellular pathogens, including M. tuberculosis, cannot be
dismissed.
Serological studies advocate that M. tuberculosis infection,
beside CMI, also evokes a strong humoral response in patients
against a variety of mycobacterial antigens (Steingart et al.,
2009). Corroborating these observations are other studies where
M. bovis BCG vaccination led to generation of mycobacterial
antigen specific IgG and IgM (Beyazova et al., 1995; Brown
et al., 2003; de Valliere et al., 2005). Some anti-M. tuberculosis
antibodies enhanced both innate and CMI responses during
mycobacterial infection (de Valliere et al., 2005). Antibodies,
through a range of mechanisms, including simple opsonization
to complicated FcR activation can regulate the fate of intracellular
pathogens. Some vaccine trials have included induction of AMI
to transduce protection against fungal diseases (Vecchiarelli
et al., 2012). A recent study has evaluated the feasibility
of using humoral immunity in vaccine development against
M. tuberculosis by comparing immunoglobulin titers (IgG and
IgA) with a variety of clinical and immunological parameters
(Niki et al., 2015). While these studies strongly support the
inclusion of evoking AMI alongside CMI in TB vaccine
development program, there is a need for systematic investigation
of mycobacterial antigens for a strong and specific humoral
response that can be employed against TB.
Surface-exposed or secreted proteins of M. tuberculosis are
customarily the targets of immune responses in the infected
host. Several M. tuberculosis proteins, including culture filtrate
proteins have been evaluated for their immunogenic properties,
such as CFP10, ESAT-6, Ag85B, ICDs etc. (Banerjee et al.,
2004; Sinha et al., 2005; Malen et al., 2008; Floss et al., 2010).
M. tuberculosis GlcB (malate synthase), MPT51 (FbpC1), and
HSPX (alpha crystalline) have also been evaluated for humoral
response in clinically asymptomatic Health-care workers with
latent infections, suggesting the possibility of these responses
to be protective (Reis et al., 2009). In this study, we have
evaluated the humoral response to M. tuberculosis H37Rv
zinc metalloprotease-1, Zmp1 (Rv0198c), a protein present in
the culture filtrate (de Souza et al., 2011). Extracellular zinc-
containing metalloproteases are ubiquitously present, quite a
few of them from pathogenic bacteria function as exotoxins,
such as, Clostridial neurotoxins, Anthrax toxins, Botulinum
neurotoxin, Bacillus sp. thermolysin etc. (Hase and Finkelstein,
1993; Miyoshi and Shinoda, 2000). These zinc-metalloproteases
are also known to elicit a strong and specific humoral response,
for which the inactivated toxin (toxoid) function as vaccine
candidate (Hase and Finkelstein, 1993; Miyoshi and Shinoda,
2000). The annotated zinc-metalloproteases from M. tuberculosis
H37Rv are, namely, Rv0198c (zmp1), Rv0563 (htpX), Rv2467
(pepN), Rv2869c (rip) and Rv3610c (ftsH), Rv1977 (Stewart
et al., 2002; Griffin et al., 2011; Kelkar et al., 2011; Mazandu
and Mulder, 2012; Schneider et al., 2014). Mutant studies of
Zmp1 in M. tuberculosis strain H37Rv and M. bovis BCG
suggested that it is essential for the intracellular survival of
the bacteria and possibly impairs inflammasome activation and
phagosome maturation (Master et al., 2008; Johansen et al.,
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2011). With these cues suggesting Zmp1 as an immunomodulator
and upon recording high antigenic index by Jameson-Wolf plot
using Protean software, we hypothesized that Zmp1 could be
a strong immunostimulant and provoke an effective humoral
response during infection. Presence of anti-Zmp1 antibodies
in TB patient sera confirmed that it is indeed expressed
during infection. We established that Zmp1 is secreted by
H37Rv under granuloma-like in vitro growth conditions and is
capable of orienting the immune response toward Th2 cytokine
microenvironment. Further, we compared the humoral response
to Zmp1 in various TB patient categories, including smear-
negative Extra-pulmonary TB cases. Presence of high titers
of anti-Zmp1 antibodies in smear-negative extra-pulmonary
tuberculosis (EPTB) cases similar to pulmonary tuberculosis
(PTB) patients that ranged from low to high bacillary load
indicated the potential of Zmp1 to evoke an effective humoral
response independent of mycobacterial load. The study points
to the potential of further exploration of mycobacterial proteins,
such as Zmp1, as antigen candidates for prime-boost vaccination
strategies or as markers for disease progression.
MATERIALS AND METHODS
Cloning, Expression, and Purification of
Zmp1 (rZmp1) Protein
The antigenic index of Rv0198c was analyzed by Protean software
(Protean 5.00, DNASTAR, Inc.; Figure 1A). Rv0198c (zmp1) gene
was amplified from the genomic DNA of H37Rv using specific
forward (5′-ataGGATCCgtgacacttgccatcccctcgg-3′) and reverse
(5′-agtCTCGAGgtcttagcctagttccagat-3′) primers. The amplicon
was cloned into BamHI and XhoI sites of pET28a vector. The
positive clones were confirmed by sequencing. pET28a-Rv0198c
construct was expressed in BL-21 DE3 cells and N-terminal
Histidine tagged recombinant Zmp1 (rZmp1) was purified under
native conditions (50 mM Tris-HCl buffer, 300 mM NaCl, pH-
8.0) by affinity chromatography using cobalt based resin. The
purified protein was dialyzed against dialysis buffer (50 mM
Tris-HCl buffer pH-8.0, 100 mM NaCl, 4% glycerol, 1 mM
PMSF) at 4◦C. Dialyzed protein was treated with polymyxin-B
agarose beads to remove endotoxins (Figure 1B). The endotoxin-
free rZmp1 protein was checked for functional activity using
casein as a substrate (Rowland et al., 1997; Coffey et al., 2000;
Grandgenett et al., 2007). Proteolytic degradation of casein can
be assessed on SDS-PAGE by monitoring for cleavage products
at lower molecular weights or apparent shift in the casein
band to lower molecular weight after proteolytic digestion.
Hydrolysis of casein by rZmp1 was performed at 37◦C for
1 h in Tris-HCl buffer (50 mM Tris-HCl pH-8.0 and 100 mM
NaCl). The reaction was stopped by adding Laemmli’s buffer
to the reaction mix followed by fractionation on SDS-PAGE.
As anticipated, hydrolysis of casein by rZmp1 has yielded two
bands corresponding to apparent molecular weights of 27 and
20 kDa (Figure 1C). Band corresponding to 20 kDa is the cleaved
product of casein which was observed when casein was incubated
with rZmp1 suggesting that the purified protein was functionally
active (Figures 1B,C).
In Vitro Mycobacterial Growth
Conditions and Western Blots
The mycobacterial strain used was M. tuberculosis H37Rv. The
growth of mycobacteria was performed as described earlier
(Ganji et al., 2016). The mycobacteria were plated on 7H10 agar
media supplemented with 10% oleic acid, albumin, dextrose,
and catalase (OADC) and incubated at 37◦C. The colonies were
picked into the 7H9 broth media supplemented with 10% OADC
and incubated at 37◦C at 180 rpm until the OD600 nm reached
0.5–0.6. The culture was checked for any contamination using
Ziehl-Neelsen (ZN) staining procedure. The culture was then
centrifuged at 3700 rpm for 7 min. The culture pellet was washed
with phosphate buffered saline (PBS) pH 7. The pellet was
then resuspended in Sauton’s media under granuloma-like stress
conditions, such as acidic pH 5.5, oxidative stress (10 mM H2O2;
Voskuil et al., 2011), Iron deprivation and Nutrient starvation for
36 h. For Nutrient stress the culture was resuspended in PBS.
For Iron deprivation, the glassware and the media were made
Iron-free as described earlier (Hall and Ratledge, 1982).
Sample Collection
A total of 295 subjects in the age group of 15–60 years were
recruited at Mahavir Hospital and Research Centre (MHRC),
Hyderabad and University of Hyderabad (UH) after taking
prior ethical committee approvals (ECR/450/Inst/AP 2013 and
UH/IEC/2014/36) and written consents from the subjects.
2–5 mL of blood was collected in vacutainers with EDTA
and later sera were separated for the experiments. The study
population was divided into four categories, namely, Clinically
Healthy donors (n = 62), TB patients (n = 121), household
contacts (n = 89), and non-specific infection controls (n = 23).
Clinically healthy donors had no symptoms of any disease at the
time of sera collection and were tested for TB-interferon-gamma
release assays (TB-IGRAs) using QuantiFERON-TB Gold (QFT)
ELISA kit (Reference# 0594-0201) and the results were analyzed
using QuantiFERON-TB Gold Analysis software (Version
2.62) as per the manufacturer’s instructions (Supplementary
Table S1). For TB patients, the sputum microscopy for AFB
was performed as per Revised National Tuberculosis Control
Programme (RNTCP), government of India, guidelines with
confirmed diagnosis of sputum, culture, and chest X-ray
in patients (http://tbcindia.nic.in/view.php?lid=3143&type=1).
Tuberculin skin test (TST) was performed in all the subjects.
TB patients were further categorized into PTB (n = 66) and
EPTB (n = 55) cases. EPTB patients were defined atleast with
one culture-positive specimen from an extra-pulmonary site, or
histological or radiological, or strong clinical evidence consistent
with active extra-pulmonary TB. Household contacts of the
respective patients were those who resided in house of the TB
patient during 3 months period for atleast seven consecutive days
prior to the diagnosis of tuberculosis. Mostly they were siblings
and spouses. The household contacts, though, were clinically
asymptomatic but many of them were Mantoux positive (Out of
89 household contacts, 60 subjects were Mantoux positive with
diameter of Induration>15 mm). Non-specific infection controls
comprised of patients with random infections other than TB
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FIGURE 1 | Rv0198c (Zmp1) protein is antigenic and purified recombinant Zmp1 (rZmp1) was functionally active. (A) Antigenicity prediction of Rv0198c
using PROTEAN software. Kyte-Doolittle plot for hydrophilicity; Emini plot for Surface probability and Jameson-Wolf analyses for Antigenic index. (B) SDS-PAGE
showing purified recombinant Rv0198c protein (rRv0198c), M: marker. Rv0198c was cloned in pET28a (+) with N-terminal 6× Histidine tag and expressed in
Escherichia coli BL21-DE3 and purified using Cobalt-based affinity chromatography. (C) SDS-PAGE depicting the functional activity of purified rRv0198c using
casein as substrate. Endotoxin-free rRv0198c was incubated with casein in presence or absence of Zinc ions. Casein was hydrolyzed by rZmp1 yielding two bands
(marked by arrowheads) corresponding to apparent molecular weights of 27 and 20 kDa.
such as viral, bacterial, and parasitic infections. Pregnant women,
terminally ill patients, immunocompromised patients, patients
undergoing any chemotherapy or with chronic illness were not
included in the study.
Enzyme Linked Immunosorbent Assay
The peripheral blood mononulear cells (PBMCs) were isolated
from blood collected from healthy donors using Ficoll gradient.
They were either left untreated or exogenously treated with 50
and 100 nM of purified, endotoxin-free rZmp1 or 0.5 µg/mL
of LPS in RPMI media supplemented with 10% FBS and kept
at 37◦C for 24 h. For measurement of cytokine levels we have
used BD OptEIA enzyme linked immunosorbent assay (ELISA)
sets and performed as per manufacturer’s instructions. For
measurement of anti-Zmp1 antibody titers, 100 ng of purified
rZmp1 in 100 µL of coating buffer was coated per well at 4◦C
overnight. The plates were then washed three times with PBST
(PBS containing 0.05% Tween-20) before blocking with 120 µL
of blocking solution (3% BSA in PBS) at 37◦C for 1 h. After
blocking, plates were washed thrice with PBST. 1:100 times
diluted (100 µL/well) sera samples were added and incubated at
37◦C for 1 h followed by five washes with PBST. Anti-Human
IgG conjugated with HRP (Sigma) was used as the secondary
antibody in 1:10000 dilution (100 µL/well) and incubated at
37◦C for 1 h. After seven washes with 1X PBST, 100 µL/well of
chromogenic substrate (Tetramethylbenzidine) was added and
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kept for incubation at 37◦C for 30 min. The reactions were
stopped using 100 µL of 2 N H2SO4. The absorbance was
measured at 450 and 570 nm in multi-well plate reader (Biotek).
To check for the cross-reactivity of rZmp1 with other anti-TB
antibodies, we have performed Western blotting for the rZmp1
using anti-ESAT6 antibody (Supplementary Figure S1). rZmp1
is not detected by the anti-ESAT6 antibody in the Western blot
(Supplementary Figure S1) and thus confirms the specificity of
rZmp1 and fidelity of rZmp1-based ELISA method to determine
the anti-Zmp1 antibody titers in the sera samples.
Graphs and Statistical Analyses
Statistical analyses were carried out using SigmaPlot software
version 11.0.0.77 (Systat Software, Inc., USA). For cytokine data,
One-way ANOVA was performed with Holm–Sidak multiple
pair-wise comparison method and the threshold for significance
was set at p < 0.05. The error bars represent the ± standard
deviation (SD) from the mean of at least three independent
experiments. For statistical analyses of anti-Zmp1 antibody titers
measured from the blood samples, One-way ANOVA on ranks
was performed with Dunn’s method for pair-wise comparison
method. The threshold for significance was set at p < 0.05. They
were represented as box plots using SigmaPlot. Within the plots,
the upper quartile of the box represents the 75th percentile and
the lower quartile for the 25th percentile. The line inside the
box represents the median. The whiskers arising from either side
of the upper half and the lower half of the box correspond to
1.5 times the interquartile range (IQR; Benjamin et al., 2013).
Any datum to the further extreme of the whiskers is termed as
outlier.
RESULTS
Zmp1 Protein is Expressed during
Infection and is Secreted under
Granuloma-Like In Vitro Growth
Conditions by M. tuberculosis H37Rv
The functionally active, endotoxin free, purified recombinant
Zmp1 (rZmp1) was used as antigen to capture anti-Zmp1
antibodies in the sera samples of TB patients (results presented
and discussed later). The presence of anti-Zmp1 antibodies
in M. tuberculosis infected patients confirmed that Zmp1 was
indeed expressed by M. tuberculosis during infection. Zmp1
was identified as one of the culture filtrate proteins of in vitro
grown H37Rv (de Souza et al., 2011). We extended the study
to check if the same holds true for granuloma-like conditions.
To study the same, H37Rv was grown under different stress
conditions known to simulate acellular caseous environment of
TB granulomas, that is, acidic pH 5.5, H2O2 induced oxidative
stress, nutrient deprivation and iron deficiency (Stallings and
Glickman, 2010). Bacteria were grown to mid-log phase and
then subjected to various stresses for 36 h. The mycobacterial
cells were then harvested and the culture supernatants separated.
Culture supernatants were then precipitated using 10% TCA
and the precipitate was used to detect presence of Zmp1
protein using Western blotting with in-house generated anti-
Zmp1 antibody (Figure 2A, upper panel). CFP10 and GroEL1,
which were probed with their respective antibodies, were used
as positive and negative controls respectively (Figure 2A, middle
and lower panel). CFP10 is a known mycobacterial secretory
protein (Malen et al., 2007, 2008) and hence was used as a positive
control for culture supernatant preparations while GroEL1 is an
intrabacterial, membrane associated protein which is not secreted
out (de Souza et al., 2011; Malen et al., 2011) and is used as
negative control. Absence of GroEL1 in the culture supernatants
indicated absence of cell lysis products in the culture supernatant
(Figure 2A, lower panel). The presence of band corresponding
to Zmp1 in Western blots suggested secretion of the protein
under all the tested stress conditions (Figure 2A, upper panel).
The assay was a qualitative check to confirm the secretion of
Zmp1, though it is possible that the levels of secreted Zmp1 in
culture supernatants may vary with stress conditions. Figure 2B
represents the Western blots with the whole bacterial lysates
as control experiment. This suggested that Zmp1 is indeed a
secreted protein, possibly secreted within granuloma of infected
host.
rZmp1 Stimulated PBMCs to Release
Th2 Class of Cytokines
We next evaluated the immunostimulatory potential of Zmp1
in terms of release of Th1/Th2 cytokines from exogenously
treated PBMCs derived from healthy volunteers to elucidate
the association of Zmp1 with CMI or AMI. To do the
same, functionally active, endotoxin free rZmp1 was used for
stimulatory assays.
Peripheral blood mononulear cells were treated with rZmp1 at
50 and 100 nM for 24 h. LPS, a known strong immunostimulant
of PBMCs, was used as a positive control (Jansky et al., 2003).
The culture supernatants were then collected to assay for the
levels of a minimal battery of cytokines. TNF-α and IL-1β
are the cytokines of innate response that stimulate the acute
phase reaction and represent initial stimulation of immune
cells. High titers of TNF-α (Untreated: 91.98 ± 27.67 pg/mL;
rZmp1 100 nM: 408.71 ± 52.96 pg/mL) and IL-1β (Untreated:
205.62 ± 65.63 pg/mL; rZmp1 100 nM: 634.34 ± 51.72 pg/mL;
Figures 3A,B) upon exogenous treatment of PBMCs with rZmp1
established that rZmp1 is indeed a strong immunostimulant,
comparable with LPS (TNF-α: 255.89 ± 107.67 pg/mL;
IL-1β: 485.46 ± 111.66 pg/mL; Figures 3A,B). We next
measured the levels of pro-inflammatory cytokines IFN-
γ and IL-12p70 and regulatory cytokines IL-4 and IL-
10. It was observed that upon treatment of PBMCs with
rZmp1 protein, there is an increased secretion of regulatory
cytokines, IL-10 (Untreated: 562.41 ± 244.02 pg/mL; rZmp1
100 nM: 1218.77 ± 270.60 pg/mL) and IL-4 (Untreated:
168.91 ± 60.62 pg/mL; rZmp1 100 nM: 292.31 ± 49.13 pg/mL;
Figures 3C,D) and while no change was observed in the levels
of IL-12p70 (Untreated: 46.32 ± 2.15 pg/mL; rZmp1 100 nM:
45.23± 8.31 pg/mL) and IFNγ (Untreated: 81.84± 31.44 pg/mL;
rZmp1 100 nM: 52.49 ± 19.43 pg/mL; Figures 3E,F). When
the ratio of IFNγ to IL-10 was considered, rZmp1 treatment
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FIGURE 2 | Zmp1 is expressed and secreted by in vitro grown Mycobacterium tuberculosis H37Rv under granuloma-like conditions. (A) The culture
supernatants of in vitro grown M. tuberculosis H37Rv under normal conditions and under various stress conditions, such as, acidic pH5.5, H2O2 induced oxidative
stress, nutrient starvation and iron depletion, were precipitated by 10% trichloroacetic acid and the resultant precipitate was subjected to Western blot using Mouse
anti-Zmp1 antibody (1:1000 dilution; Upper panel). Rabbit anti-CFP10 antibody (1:1000 dilution) against CFP10, a culture filtrate protein 10, was used as a positive
control (Middle Panel) and Mouse anti-GroEL1 antibody (1:1000 dilution) against GroEL1, a cytoplasmic chaperone was used as a negative control (Lower Panel) to
evaluate for cell lysis products in supernatants. The absence of band corresponding to GroEL1 in the supernatant fractions suggests the purity of culture filtrate
preparations. (B) Figure represents the Western blots with the whole bacterial lysates as control experiment.
showed lower IFNγ:IL-10 ratio of 0.30 ± 0.07 as compared to
untreated (1 ± 0.13) or LPS (0.54 ± 0.10) treated (Figure 3G).
This indicated that rZmp1 promoted a Th2 immune response.
Summing up, these experiments indicated that the secreted
M. tuberculosis Zmp1 should incline the immune system toward
Th2 response, promoting humoral immunity.
With the above experiments indicating that Zmp1 induces
Th2 response, we next assessed if this is manifested in the form
of anti-Zmp1 antibody production in TB patients. To verify the
same, we measured anti-Zmp1 antibodies in the sera samples
of TB patients using rZmp1 as the bait antigen in ELISA based
assays.
Zmp1 Elicited a Strong B-cell Response
Which Was Specific for Tuberculosis (TB)
Infection
The humoral response of the host against mycobacterial secretory
protein, Zmp1 was scored in a study population comprising
295 subjects. This included four groups, TB patients, Healthy
controls, Household contacts of TB patients and volunteers
with non-specific infections. Purified rZmp1 was used as bait
antigen in the indirect ELISA to score for the anti-Zmp1
antibodies in the serum samples of healthy (n = 62), TB
patients (n = 121), household contacts (n = 89), and non-
specific infection control samples (n = 23; Figure 4A). We
observed that there was a significant increase (p < 0.001) in the
absorbance at 450 nm corresponding to the anti-Zmp1 antibody
titers in TB patient sera as compared to the healthy or household
contacts or non-specific infection controls (Figure 4A). The
median values for the Healthy was 0.702 (IQR: 0.506–0.893),
TB patients was 1.264 (IQR: 0.961–1.982), household contacts
was 0.606 (IQR: 0.486–0.78) and non-specific infection control
was 0.539 (IQR: 0.394–0.708) showing distinct difference of TB
patients from other groups. The non-reactivity of rZmp1 to sera
samples of non-specific infection controls clearly indicated that
the rZmp1 did not cross-react with the antibodies generated
due to other infections in human host. In addition, negligible
absorbance observed in sera of healthy donors and Household
contacts strongly points to the specificity of rZmp1 to TB
infection. This clearly indicated that Zmp1 could elicit a strong
humoral response that was specific to TB patients and could
clearly distinguish TB patient category from all other categories,
including asymptomatic household contacts.
Zmp1 Elicits Strong B-cell Response
Independent of Mycobacterial Load in
TB Patients
Having seen that rZmp1 stimulated release of Th2 cytokines
over Th1 in PBMCs and accordingly Zmp1 elicited a strong
B-cell response that could be detected in terms of high anti-
Zmp1 IgG titers in TB patients, we next checked if these titers
differed between PTB (n = 66) and EPTB (n = 55) cases. This
was important as all EPTB patients were sputum smear-negative
but recorded presence of mycobacteria by acid-fast bacilli (AFB)
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FIGURE 3 | Treatment of PBMCs with recombinant Zmp1 protein inclines the immune status to Th2 response. Cytokine profiles of the PBMCs either
untreated or treated with LPS, 50 nM rZmp1 and 100 nM rZmp1 was estimated. (A) TNFα, (B) IL-1β, (C) IL-10, (D) IL-4, (E) IL-12p70, (F) IFNγ titers were measured
using capture ELISA. (G) Ratio of IFNγ:IL-10. All the experiments were performed more than three times. Statistical analyses were done using one-way ANOVA with
Holm-Sidak multiple pair-wise comparison method. Error bars represent ±SD (standard deviation). ∗ Represents p < 0.05.
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FIGURE 4 | rRv0198c ELISA was specific for tuberculosis (TB) infection. (A) Box plots representing titers of anti-Rv0198c antibody titers as indicated by
values at Absorbance 450 nm in Healthy, TB, Household or patient contacts and Non-specific infection control. ∗The differences in Abs450 values for TB vs. Healthy;
TB vs. Household contacts and TB vs. non-specific infection controls were highly significant and a p-value of <0.001 was observed in all the three cases. (B) The
box plots representing the anti-Rv0198c antibody titers in Healthy controls, Pulmonary TB patients and Extra-pulmonary TB patients. Statistical analyses were done
using one-way ANOVA on ranks was performed with Dunn’s method for pair-wise comparison method. ∗ Represents p < 0.05.
staining and caseous necrosis in their biopsy samples, suggesting
localized mycobacterial load. We observed that the median
values for both PTB and EPTB cases were approximately similar,
viz.; for PTB it was 1.257 (IQR: 0.956–1.8) and for EPTB, it
was 1.421 (IQR: 0.979–2.259; Figure 4B). We then compared
the anti-Zmp1 titers in PTB patients with various gradients
of mycobacterial load. Table 1 lists the representative ELISA
readings of PTB patients ranging from a high bacilli load (3+)
to smear negative, synonymous with extremely low bacilli titers,
clearly showing humoral response to Zmp1 was independent
of M. tuberculosis load. This observation was significant, as it
suggested that Zmp1 could elicit a strong humoral response
even in paucibacillary PTB cases and can detect EPTB cases
significantly.
Humoral Response to Zmp1 Was
Detected Only in Active TB Cases and
Not in Their Household Contacts
Some of the reports have indicated antibodies against specific
M. tuberculosis antigens in the sera of clinically healthy, latently
infected Health-care workers (Reis et al., 2009). With the anti-
Zmp1 antibodies detected in active EPTB and even in active
paucibacillary PTB cases (Table 1), we wanted to check if anti-
Zmp1 titers were also detectable in the respective household
contacts. These household contacts had stayed with active
patients for at the least seven consecutive days during the
3 months prior to the diagnosis of TB. They were expected to
be exposed to M. tuberculosis though it is reported that EPTB
patients, specifically those with tissue TB, are unlikely to transmit
the bacilli. Most of these clinically asymptomatic contacts were
tested positive for Mantoux’s test (Out of 89 household contacts,
60 subjects were Mantoux positive with diameter of Induration
>15 mm) and hence may represent possible cases of latent TB.
To evaluate that, ELISA readings of EPTB (n = 55) and their
respective household contacts (n = 55) and PTB (n = 66) and
their household contacts (n= 34) were plotted (Figures 5A,B). It
was observed that compared to EPTB patient contacts (Median:
0.663; IQR: 0.524–0.808) or PTB patient contacts (Median:
0.570; IQR: 0.387–0.630), titers of anti-Zmp1 antibody were
distinctly high in EPTB patients (Median: 1.421; IQR: 0.979–
2.259; p< 0.001) or PTB patients (Median: 1.257; IQR: 0.956–1.8;
p < 0.001), respectively (Figures 5A,B), suggesting that Zmp1
humoral response is restricted to active infection cases as against
asymptomatic household contacts including Mantoux positive
cases under the category which may be possible latent subjects.
DISCUSSION
Till recently, TB vaccine program was driven by the belief
that protective immunity against M. tuberculosis infection is
chiefly because of CMI generated by Th1 microenvironment.
The majority of candidate vaccines were focused on improving
CMI either by engineering the present BCG vaccine or
using mycobacterial antigens that elicited Th1 responses
as boosters after BCG priming. Interestingly, the vaccine
strategies that use the whole cell (such as M. indicus
pranii) has reached phase III of clinical trials (Weiner and
Kaufmann, 2014; Tye et al., 2015). The success of this may
be owing to a balanced stimulation of both CMI and AMI
wings rather than trying to bias the same toward CMI.
Additionally, with monoclonal antibodies conferring passive
immunity against several intracellular pathogens, including
M. tuberculosis, humoral response to TB is being explored with
a new enthusiasm.
In this study, we deliberated on the immunomodulatory
function of a secreted M. tuberculosis protein Zinc
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TABLE 1 | Representative table to show that pulmonary TB (PTB) cases
with varying loads of bacilli load in sputum does not show variation in
their Abs450 nm when detected by rZmp1 ELISA test.
Sample no. AFB (Bacilli load) Abs450
PTB# 1 PI -VE 1.260667
PTB# 2 PI -VE 1.297333
PTB# 3 PI -VE 1.407333
PTB# 4 PI -VE 1.716
PTB# 5 PI -VE 1.936333
PTB# 6 PI -VE 2.3335
PTB# 7 PI 1+ 1.127333
PTB# 8 PI 1+ 1.178333
PTB# 9 PI 1+ 1.725667
PTB# 10 PI 1+ 1.978333
PTB# 11 PI 1+ 2.317333
PTB# 12 PI 2+ 1.249667
PTB# 13 PI 2+ 1.319667
PTB# 14 PI 2+ 1.773
PTB# 15 PI 2+ 1.800333
PTB# 16 PI 2+ 2.487
PTB# 17 PI 3+ 1.107
PTB# 18 PI 3+ 1.274333
PTB# 19 PI 3+ 1.564667
PTB# 20 PI 3+ 2.67
PI 1+ indicates more than 100 acid-fast bacilli (AFB) in sputum, PI 2+ indicates
more than 200 acid-fast bacilli in sputum, PI 3+ indicates more than 300 acid-fast
bacilli in sputum from 100 microscopic fields, PI -VE indicates no acid-fast bacilli in
sputum.
metalloprotease-1. M. tuberculosis Zmp1 is a well characterized
protein that alters phagosome maturation and is considered
essential for intracellular survival of M. tuberculosis. With the
X-ray structure available, this protein has been screened for
small molecule inhibitors to evaluate it as a potential drug target
(Ferraris et al., 2011; Mori et al., 2014). Zmp1 works optimally
under slightly acidic conditions with neuropeptides as possible
substrates (Petrera et al., 2012). It was also shown to be involved
in inflammasome activation (Master et al., 2008), suggesting
that it definitely has immunomodulatory function besides its
role in regulating phagosome maturation. Protein sequence
analyses by Jameson-Wolf plot using Protean software, which
recorded high antigenicity indices based on surface probability
and hydrophobicity of its amino-acid sequence of Zmp1 further
supported the notion that apart from an active enzyme, it can
also be a B-cell stimulant (Figure 1A).
We confirmed the secretory nature of Zmp1 in granuloma-
like in vitro growth conditions and concluded that Zmp1
could indeed be released out in the extracellular milieu when
M. tuberculosis is growing in acidic, nutrient deprived and
oxidatively stressed acellular environment at the center of TB
granulomas (Figure 2). In addition to that, we also observed
that it is a strong immune-stimulant and could stimulate mono-
nuclear cells to release high titers of TNF-α and IL-1β, the shock
inducing cytokines that also start the innate mechanisms toward
acute phase reaction. However, subsequently, it was not the
pro-inflammatory, but Th2 cytokines that were pre-dominantly
released upon rZmp1 stimulation of PBMCs (Figure 3).
Corroborating the Th2 response, in a cohort of about 121
TB patients, high titers of anti-Zmp1 antibodies could be
recorded (Figure 4). This study revealed yet another facet of
M. tuberculosis Zmp1 as a highly immunogenic mycobacterial
antigen that could elicit strong and specific humoral response in
TB patients.
FIGURE 5 | rRv0198c ELISA detected all active TB cases with high specificity and sensitivity. (A) Box plots representing titers of anti-Rv0198c antibody
titers as indicated by values at Absorbance 450 nm in Healthy, extra-pulmonary TB (EPTB), EPTB patient contacts (Household contacts of EPTB patients). (B) Box
plots representing titers of anti-Rv0198c antibody titers as indicated by values at Absorbance 450 nm in Healthy, pulmonary TB (PTB), PTB patient contacts
(Household contacts of PTB patients). ∗The differences in Abs450 values for PTB vs. Healthy; PTB vs. PTB Household contacts; EPTB vs. Healthy; EPTB vs. EPTB
Household contacts were highly significant and a p-value of <0.001 was observed in all the cases. Statistical analyses were done using one-way ANOVA on ranks
was performed with Dunn’s method for pair-wise comparison method.
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There are many reports analyzing the levels of IgG antibody
titers against M. tuberculosis antigens, secretory or otherwise, in
different clinical stages (Wu et al., 2010; Baumann et al., 2014,
2015). The studies also claim that these antibodies are present
during active disease, but reduce upon decrease in bacterial load
with treatment (Singh et al., 2005). That would mean antibody
titers are bacterial load dependent and a low bacterial infection
may not sufficiently trigger a good humoral response. To check
the same, we compared the anti-Zmp1 antibody titers in patients
with high or low bacillary loads. To our surprise, anti-Zmp1
titers were equally high in paucibacillary cases as in patient with
sputum bacilli score of 3+ (Figure 5B; Table 1). This suggested
that a very low dose of M. tuberculosis Zmp1 could induce
very strong and specific B-cell response, a property that can be
suitably explored for prime–boost vaccination strategy. In total,
with the evidence that Zmp1 is secreted by active M. tuberculosis
in granuloma-like growth conditions and stimulated PBMCs to
release Th2 class of cytokines, one may hypothesize that very low
concentration of this protein when released in the granulomas
of infected host, stimulate the neighboring mono-nuclear cells to
eventually generate a Th2 immune response that supports B-cell
specific immunity toward Zmp1 resulting in high titers of anti-
Zmp1 antibodies in patients. However, unlike reported humoral
response to GlcB (malate synthase), MPT51 (FbpC1) and HSPX
(alpha crystalline) in latent TB cases (Reis et al., 2009), anti-
Zmp1 antibodies could not be detected significantly in healthy
household contacts who were asymptomatic, Mantoux’s positive
and possibly represent latently infected population in this study.
Likewise, we observed that rZmp1 ELISA was highly specific
for TB cases, both PTB and EPTB (Figure 4B). The group
comprising of non-specific infections were used to rule out
if, Zmp1 cross-reacts with antibodies generated against other
bacterial or viral proteins. This group had patients with random
infections other than TB such as viral, bacterial, and parasitic
infections. Non-reactivity of rZmp1 with antibodies in the
sera of non-specific infection controls as indicated by low-
absorbance values (Figure 4A) points to the specificity of rZmp1
to distinctly differentiate TB cases from all other categories.
This suggests the potential of rZmp1 ELISA as a disease marker
which can be further explored. Identification EPTB disease
remains challenging for reasons like diffused symptoms, low
M. tuberculosis load at the site of infection and difficulties in
obtaining clinical specimens from deep-seated organs (Lawn and
Zumla, 2012). Dependence on cultures for EPTB frequently leads
to substantial delays, compromising patient care and spread of
infection to others. Though serological tests are less acceptable in
the field of TB detection, the problem possibly lies in the selection
of an antigen that shows a good serological response even
when infection load is less. In comparison with microscopy and
cultures, ELISA based serological tests offer several advantages
such as in terms of time, infrastructure and ease of sample
collection in the form of peripheral blood.
In this study, we revealed hitherto unknown immunogenic
property of M. tuberculosis Zmp1. Zmp1 is a strong
M. tuberculosis specific immune-stimulant, the properties of
which can be further explored both as a potential vaccine
candidate or a disease marker. The possibility of taking the study
on antigenicity of Zmp1 to the next level by using larger cohort,
blinded samples and multi-centric study is very stimulating from
both scientific point of view and translational research.
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FIGURE S1 | Cross-reactivity check of anti-Zmp1 antibody and rZmp1.
(A) Recombinant mycobacterial antigens, ESAT6 (5 µg), CFP10 (5 µg), and Zmp1
(5 µg) were loaded on to 15% SDS-PAGE followed by Western blot with Mouse
anti-Zmp1 antibody. The corresponding Ponceau S stained blot showing
transferred protein is provided. (B) Recombinant mycobacterial antigens, ESAT6
(5 µg) and Zmp1 (5 µg) were loaded on to 15% SDS-PAGE followed by Western
blot with rabbit anti-ESAT6 antibody (1:1000 dilution). The corresponding
Ponceau S stained blot showing transferred protein is provided.
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